Obigen Pharma Inc. (TPEX:7876)
Taiwan
· Delayed Price · Currency is TWD 37.40
+0.40 (1.08%)
At close: Feb 26, 2026
Obigen Pharma Statistics
Total Valuation
Obigen Pharma has a market cap or net worth of TWD 4.00 billion. The enterprise value is 3.43 billion.
| Market Cap | 4.00B |
| Enterprise Value | 3.43B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Obigen Pharma has 106.92 million shares outstanding. The number of shares has increased by 39.47% in one year.
| Current Share Class | 106.92M |
| Shares Outstanding | 106.92M |
| Shares Change (YoY) | +39.47% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.25% |
| Owned by Institutions (%) | n/a |
| Float | 106.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.59 |
| P/TBV Ratio | 4.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.34 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -20.44 |
Financial Position
The company has a current ratio of 24.54, with a Debt / Equity ratio of 0.06.
| Current Ratio | 24.54 |
| Quick Ratio | 24.00 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.53 |
| Interest Coverage | -157.14 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -18.12% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -4.88M |
| Employee Count | 57 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 37.45 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 49.33 |
| Average Volume (20 Days) | 142,438 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -293.22M |
| Pretax Income | -278.20M |
| Net Income | -278.20M |
| EBITDA | -194.46M |
| EBIT | -293.22M |
| Earnings Per Share (EPS) | -2.62 |
Balance Sheet
The company has 653.86 million in cash and 88.59 million in debt, giving a net cash position of 565.26 million or 5.29 per share.
| Cash & Cash Equivalents | 653.86M |
| Total Debt | 88.59M |
| Net Cash | 565.26M |
| Net Cash Per Share | 5.29 |
| Equity (Book Value) | 1.54B |
| Book Value Per Share | 14.56 |
| Working Capital | 717.53M |
Cash Flow
In the last 12 months, operating cash flow was -160.71 million and capital expenditures -7.26 million, giving a free cash flow of -167.96 million.
| Operating Cash Flow | -160.71M |
| Capital Expenditures | -7.26M |
| Free Cash Flow | -167.96M |
| FCF Per Share | -1.57 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Obigen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -39.47% |
| Shareholder Yield | -39.47% |
| Earnings Yield | -6.96% |
| FCF Yield | -4.20% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |